# MorphoSys (Novartis)

Source: https://onco.cc/companies/morphosys/  
OnCo record `morphosys` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

German antibody company that acquired Constellation's BET inhibitor pelabresib and was itself bought by Novartis in 2024.

## Summary

MorphoSys, based in Planegg near Munich, was the German antibody company that developed tafasitamab and acquired Constellation Pharmaceuticals for the BET inhibitor pelabresib, before Novartis bought it in 2024; OnCo marks the record as historic. Tafasitamab, sold as Monjuvi, is a CD19 antibody for diffuse large B-cell lymphoma whose rights moved to Incyte, and pelabresib, acquired with Constellation in 2021, was studied in myelofibrosis in the MANIFEST-2 trial. OnCo links it to diffuse large B-cell lymphoma, to CD19 as a target, to epigenetic drugs and monoclonal antibodies, and to Novartis. Whether pelabresib justifies the price Novartis paid is the question that outlived the company. Tafasitamab has its own page.

## Fields

- Kind: Company
- Status: historic
- Last checked: 2026-09-04
- HQ: Planegg
- Type: biotech
- Website: https://www.morphosys.com

## Sources

- Official website: https://www.morphosys.com

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- fronts: [Epigenetic & Transcriptional Therapy](https://onco.cc/fronts/epigenetics/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)](https://onco.cc/technologies/epigenetic-drugs/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- companies: [Novartis](https://onco.cc/companies/novartis/)
- drugs: [Tafasitamab](https://onco.cc/drugs/tafasitamab/)
- trials: [L-MIND](https://onco.cc/trials/l-mind/), [MANIFEST-2](https://onco.cc/trials/manifest-2/)
- roadmaps: [Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome](https://onco.cc/roadmaps/epigenetics-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/morphosys.json